XML 50 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Disclosures (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Revenue and Expenses

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

 

 

(in thousands)

 

Total revenue

 

$

138,103

 

 

$

101,214

 

External costs incurred by product candidate (target):

 

 

 

 

 

 

CX-904 (EGFRxCD3)

 

 

7,487

 

 

 

2,790

 

CX-2051 (EpCAM)

 

 

17,846

 

 

 

9,966

 

CX-801 (IFNα2b)

 

 

2,505

 

 

 

11,620

 

CX-2029 (CD71)

 

 

671

 

 

 

2,608

 

Other wholly owned and partnered programs

 

 

6,404

 

 

 

6,490

 

General research and development expenses

 

 

16,288

 

 

 

9,906

 

 Total external costs

 

 

51,201

 

 

 

43,380

 

 Internal costs

 

 

32,181

 

 

 

34,300

 

 Research and development expenses

 

 

83,382

 

 

 

77,680

 

General and administrative expenses

 

 

29,726

 

 

 

30,018

 

Income (loss) from operations

 

 

24,995

 

 

 

(6,484

)

Interest income

 

 

7,136

 

 

 

9,837

 

Other income (expense), net

 

 

(38

)

 

 

(30

)

Income/(loss) before income taxes

 

 

32,093

 

 

 

3,323

 

Provision for income taxes

 

 

224

 

 

 

3,892

 

Net income (loss)

 

$

31,869

 

 

$

(569

)